Eli Lilly and Co. has filed several new lawsuits against medical spas, wellness centers, and other institutions, claiming that these organizations have used Eli Lilly's Mounjaro and Zepbound when referring to their own products. Eli Lilly stated in a letter to patients that the company does not provide its drug ingredients to compounded pharmaceutical companies. Last year, Eli Lilly and its competitor, Novo Nordisk, filed multiple lawsuits in an attempt to stop companies selling unapproved medications, with demand being high for weight loss and diabetes medications globally. So far, Eli Lilly has filed 11 lawsuits accusing these companies of selling counterfeit drugs under the name of exenatide (the generic name for Mounjaro and Zepbound), trademark infringement, false advertising and unfair competition. It is known that US regulators allow pharmacies to compound shortage drugs, which are called compounded drugs. Eli Lilly is trying to link these products with blatant counterfeit products, and stated on Thursday that the company "has discovered issues of safety, sterility, and efficacy involving compounded drugs advertised as exenatide."
礼来提起多起诉讼 拟加大对Zepbound仿冒药的打击力度
Eli Lilly and Co has filed multiple lawsuits and plans to increase efforts to crack down on counterfeit Zepbound drugs.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.